Latest news

• GSK two-drug trial in untreated HIV raises Gilead rivalry

  Along with dolutegravir/lamivudine for treatment-naïve patients, it has also been granted regulatory approval for Juluca, a combination of dolutegravir and Johnson &Johnson’s non-nucleoside RTI Edurant (rilpivirine) for

• Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

  It combines ViiV’s own Tivicay (dolutegravir) the most widely prescribed integrase inhibitor worldwide, and J&J’s  Edurant (rilpivirine).

• ViiV’s two-drug HIV combo backed by CHMP

  The advisory committee issued a positive opinion for Juluca - which combines ViiV’s integrase inhibitor Tivicay (dolutegravir) with a non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine) developed by Johnson &Johnson’s

• GSK’s ViiV gets US okay for two-drug HIV regimen

  Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant. The FDA has approved a dual therapy for HIV from GlaxoSmithKline’s ViiV joint venture with Johnson &Johnson, which ... The US regulator gave a green light to Juluca, which combines

• ViiV files two-drug HIV maintenance regimen

  inhibitor Edurant (rilpivirine) in the US and EU.